Please login to the form below
Bridge Biotherapeutics
This page shows the latest Bridge Biotherapeutics news and features for those working in and with pharma, biotech and healthcare.
FDA clears wider use for Boehringer’s Ofev in lung disease
followed earlier deals with Bridge Biotherapeutics for an Ofev follow-up and Yuhan focusing on lover fibrosis.
Latest news
-
Boehringer bolsters NASH pipeline with Enleofen link-up
The last couple of years have seen the German group license an Ofev follow-up from Bridge Biotherapeutics and agree an $870m tie-up with Yuhan for a NASH candidate.
-
Biogen loses another pipeline drug to toxicity concerns
Boehringer has its eyes on a follow-up treatment for IPF, and in July licensed an early-stage autotaxin inhibitor BBT-877 from South Korea’s Bridge Biotherapeutics in a
-
Boehringer’s head of pharma heads for the exit
a new approach to cancer immunotherapy, a 1.1bn licensing deal for an Ofev follow-up from Bridge Biotherapeutics, and an $870m tie-up with Yuhan for a non-alcoholic steatohepatitis
-
Boehringer taps Korea’s Bridge for Ofev follow-up
Bridge Biotherapeutics to try to extend the franchise. ... Bridge stands to receive up to 1.1bn ($1.24bn) under the terms of the deal, including 45m in upfront and near-term payments.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
